Trevi Therapeutics Inc
NASDAQ:TRVI

  • LAST PRICE
    2.9100
  • TODAY'S CHANGE (%)
    0.1800 (6.5934%)
  • Bid / Lots
    2.7000/ 40
  • Ask / Lots
    3.1700/ 1
  • Open / Previous Close
    2.7300 / 2.7300
  • Day Range
    2.6600
    2.9300
  • 52 Week Range
    0.9700
    4.0000
  • Volume
    1,757,363

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
TRVI
Trevi Therapeutics Inc
209.8M
-6.6x
---
SLDB
Solid Biosciences Inc
209.0M
-1.8x
---
OKUR
Onkure Therapeutics Inc
213.3M
-1.3x
---
LXEO
Lexeo Therapeutics Inc
205.0M
-2.2x
---
CRBP
Corbus Pharmaceuticals Holdings Inc
203.8M
-3.7x
---
XBIT
XBiotech Inc
201.7M
-6.4x
---
As of 2024-11-22

Company Information

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Contact Information

Headquarters
195 Church St Fl 14NEW HAVEN, CT, United States 06510-2009
Phone
203-304-2499
Fax
203-304-2434

Executives

Non-Executive Chairman of the Board
David Meeker
President, Chief Executive Officer, Chief Financial Officer, Director
Jennifer Good
Co-Founder, Chief Science Officer
Thomas Sciascia
Chief Financial Officer
Lisa Delfini
Chief Development Officer, Director
James Cassella

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$209.8M
Revenue (TTM)
$0.00
Shares Outstanding
76.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.97
EPS
$-0.44
Book Value
$1.21
P/E Ratio
-6.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.